<DOC>
	<DOCNO>NCT00756249</DOCNO>
	<brief_summary>The primary purpose study determine whether carbamylated erythropoietin ( CEPO ) safe treatment patient suffer acute ischemic stroke .</brief_summary>
	<brief_title>Safety Study Carbamylated Erythropoietin ( CEPO ) Treat Patients With Acute Ischemic Stroke</brief_title>
	<detailed_description>Acute ischemic stroke major cause death severe disability . There one approve pharmacological treatment , Alteplase , administer within 3 hour symptom onset . Consequently , 2-3 % patient world wide ischemic stroke treat . The naturally occur hormone , erythropoietin ( EPO ) , able protect various neuronal tissue ischemic injury beneficial animal model acute ischemic stroke . However , treatment stroke EPO undesirable due ability stimulate production red blood cell promote blood coagulate . Lu AA24493 modify ( carbamylated ) version EPO , neuroprotective without haematopoietic side effect . Lu AA24493 develop treatment patient acute ischemic stroke . In safety study single dos Lu AA24493 , patient receive Lu AA24493 within 12-48 hour symptom onset .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Age 50 90 year Clinical diagnosis acute ischemic stroke Measurable strokerelated deficit Patient stable Treatment initiate 12 hour 48 hour onset stroke Expected hospital stay least 72 hour study medication If female childbearing potential Primary intracerebral haemorrhage ( ICH ) , parenchymal haemorrhagic transformation infarction ( type PHI PHII define ECASS ) , subarachnoid haemorrhage ( SAH ) , arteriovenous malformation ( AVM ) , cerebral aneurysm , cerebral neoplasm Treated thrombolytic &lt; 24 hour ( &gt; 24 hour exclude ICH eligible ) Score &gt; 0 NIHSS item 1a Prestroke mRS score &gt; 1 Uncontrolled hypertension Previous treatment erythropoietin Clinically significant abnormal ECG Cerebral pathology Received donate blood within previous 3 month</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Acute ischemic stroke</keyword>
	<keyword>Erythropoietin</keyword>
	<keyword>Carbamylated</keyword>
	<keyword>Neuroprotection</keyword>
</DOC>